Published in J Virol on June 06, 2012
Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus. J Neurovirol (2014) 0.98
Targeting host factors to treat West Nile and dengue viral infections. Viruses (2014) 0.92
Open drug discovery for the Zika virus. F1000Res (2016) 0.91
Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity. Antiviral Res (2014) 0.90
Structures of NS5 Methyltransferase from Zika Virus. Cell Rep (2016) 0.89
The bioactive lipid 4-hydroxyphenyl retinamide inhibits flavivirus replication. Antimicrob Agents Chemother (2014) 0.88
Illustrating and homology modeling the proteins of the Zika virus. F1000Res (2016) 0.86
Oxidative stress influences positive strand RNA virus genome synthesis and capping. Virology (2014) 0.83
West Nile virus drug discovery. Viruses (2013) 0.82
Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection. Antiviral Res (2015) 0.80
Benzothiazole and Pyrrolone Flavivirus Inhibitors Targeting the Viral Helicase. ACS Infect Dis (2015) 0.80
N-Desmethylclozapine, Fluoxetine and Salmeterol inhibit post-entry stages of dengue virus life-cycle. Antimicrob Agents Chemother (2016) 0.79
Murine Efficacy and Pharmacokinetic Evaluation of the Flaviviral NS5 Capping Enzyme 2-Thioxothiazolidin-4-One Inhibitor BG-323. PLoS One (2015) 0.77
A Sensitive and Robust High-Throughput Screening Assay for Inhibitors of the Chikungunya Virus nsP1 Capping Enzyme. PLoS One (2016) 0.76
Subgenomic reporter RNA system for detection of alphavirus infection in mosquitoes. PLoS One (2013) 0.76
The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antiviral Res (2016) 0.76
Putting an 'End' to HIV mRNAs: capping and polyadenylation as potential therapeutic targets. AIDS Res Ther (2013) 0.76
Development of a S-adenosylmethionine analog that intrudes the RNA-cap binding site of Zika methyltransferase. Sci Rep (2017) 0.75
Modification of S-Adenosyl-l-Homocysteine as Inhibitor of Nonstructural Protein 5 Methyltransferase Dengue Virus Through Molecular Docking and Molecular Dynamics Simulation. Drug Target Insights (2017) 0.75
Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy. ACS Chem Biol (2015) 0.75
Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science (1985) 8.54
Improved protein-ligand docking using GOLD. Proteins (2003) 7.94
An RNA cap (nucleoside-2'-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO J (2002) 3.87
2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature (2010) 3.49
Structure and function of flavivirus NS5 methyltransferase. J Virol (2007) 2.93
Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol (2011) 2.85
Update on the global spread of dengue. Int J Antimicrob Agents (2010) 2.02
Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol (2005) 1.97
Structural and functional analysis of methylation and 5'-RNA sequence requirements of short capped RNAs by the methyltransferase domain of dengue virus NS5. J Mol Biol (2007) 1.69
A structural basis for the inhibition of the NS5 dengue virus mRNA 2'-O-methyltransferase domain by ribavirin 5'-triphosphate. J Biol Chem (2004) 1.65
The flavivirus NS5 protein is a true RNA guanylyltransferase that catalyzes a two-step reaction to form the RNA cap structure. RNA (2009) 1.58
Small molecule inhibitors that selectively block dengue virus methyltransferase. J Biol Chem (2010) 1.40
Analysis of flavivirus NS5 methyltransferase cap binding. J Mol Biol (2008) 1.27
Recognition of RNA cap in the Wesselsbron virus NS5 methyltransferase domain: implications for RNA-capping mechanisms in Flavivirus. J Mol Biol (2008) 1.25
Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy (2008) 1.22
Phosphorylation of yellow fever virus NS5 alters methyltransferase activity. Virology (2008) 1.13
Structural bases for substrate recognition and activity in Meaban virus nucleoside-2'-O-methyltransferase. Protein Sci (2007) 1.13
Identification and characterization of inhibitors of West Nile virus. Antiviral Res (2009) 1.00
Monoclonal antibodies to the West Nile virus NS5 protein map to linear and conformational epitopes in the methyltransferase and polymerase domains. J Gen Virol (2009) 0.96
Focus on flaviviruses: current and future drug targets. Future Med Chem (2009) 0.94
A simple method for calculating the dissociation constant of a receptor (or enzyme).unlabeled ligand complex from radioligand displacement measurements. Arch Biochem Biophys (1991) 0.87
Infectious alphavirus production from a simple plasmid transfection+. Virol J (2011) 0.87
The flaviviral methyltransferase is a substrate of Casein Kinase 1. Virus Res (2009) 0.86
Anti-Sindbis activity of flavanones hesperetin and naringenin. Biol Pharm Bull (2003) 0.86
A high-throughput screening assay for the identification of flavivirus NS5 capping enzyme GTP-binding inhibitors: implications for antiviral drug development. J Biomol Screen (2011) 0.85
Analysis of RNA binding by the dengue virus NS5 RNA capping enzyme. PLoS One (2011) 0.82
A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology (2005) 2.60
The flavivirus NS5 protein is a true RNA guanylyltransferase that catalyzes a two-step reaction to form the RNA cap structure. RNA (2009) 1.58
Suppression of RNA interference increases alphavirus replication and virus-associated mortality in Aedes aegypti mosquitoes. BMC Microbiol (2009) 1.56
Analysis of flavivirus NS5 methyltransferase cap binding. J Mol Biol (2008) 1.27
Highly potent triazole-based tubulin polymerization inhibitors. J Med Chem (2007) 1.13
Stimulation of the Raf/MEK/ERK cascade is necessary and sufficient for activation and Thr-160 phosphorylation of a nuclear-targeted CDK2. J Biol Chem (2002) 1.05
Requirement of activated Cdc42-associated kinase for survival of v-Ras-transformed mammalian cells. Mol Cancer Res (2005) 1.03
Focus on flaviviruses: current and future drug targets. Future Med Chem (2009) 0.94
Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity. Cancer Res (2009) 0.93
Three-dimensional structure-activity relationship modeling of cocaine binding to two monoclonal antibodies by comparative molecular field analysis. J Mol Biol (2003) 0.90
Purification and mass spectrometric analysis of the mu opioid receptor. Brain Res Mol Brain Res (2003) 0.87
Infectious alphavirus production from a simple plasmid transfection+. Virol J (2011) 0.87
A high-throughput screening assay for the identification of flavivirus NS5 capping enzyme GTP-binding inhibitors: implications for antiviral drug development. J Biomol Screen (2011) 0.85
3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies. J Med Chem (2005) 0.83
Discovery of novel triazole-based opioid receptor antagonists. J Med Chem (2006) 0.82
Analysis of RNA binding by the dengue virus NS5 RNA capping enzyme. PLoS One (2011) 0.82
Exploring novel targets for antimalarial drug discovery: plasmodial protein kinases. Infect Disord Drug Targets (2010) 0.82
3D-QSAR comparative molecular field analysis on delta opioid receptor agonist SNC80 and its analogs. J Mol Graph Model (2005) 0.80
Influence of the structural diversity of data sets on the statistical quality of three-dimensional quantitative structure-activity relationship (3D-QSAR) models: predicting the estrogenic activity of xenoestrogens. Chem Res Toxicol (2002) 0.78
PAIRpred: partner-specific prediction of interacting residues from sequence and structure. Proteins (2013) 0.78
Evaluation of broad spectrum protein kinase inhibitors to probe the architecture of the malarial cyclin dependent protein kinase Pfmrk. Bioorg Med Chem Lett (2007) 0.78
Hemodynamic response profile predicts susceptibility to cocaine-induced toxicity. Eur J Pharmacol (2003) 0.77
Three-dimensional structure-activity relationship modeling of digoxin inhibition and docking to Na+,K+-ATPase. Ann N Y Acad Sci (2003) 0.77
Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways. Bioorg Med Chem (2009) 0.77
Malarial kinases: novel targets for in silico approaches to drug discovery. Methods Mol Biol (2013) 0.76
Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones. Bioorg Med Chem Lett (2009) 0.76
Regulation of flavivirus RNA synthesis and capping. Wiley Interdiscip Rev RNA (2013) 0.76
Structural model of the Plasmodium CDK, Pfmrk, a novel target for malaria therapeutics. J Mol Graph Model (2005) 0.76
Highly Sensitive and Rapid Detection of Salmonella typhimurium Using a Colorimetric Paper Based Analytical Device Coupled with Immunomagnetic Separation. Anal Chem (2017) 0.75
Activation and phosphorylation on Thr-160 of nuclear-targeted CDK2 Is ERK dependent. Ann N Y Acad Sci (2002) 0.75